Articles from Vitroscope AS

Vitroscope AS, a biotech company developing perfusion platforms for studying immune activity, treatment responses and disease mechanisms in real time, has raised $7 million, comprising a $5 million seed round and $2 million in non-dilutive funding. The funding will support the commercial rollout of vitro.alive, the company’s benchtop platform, and validation of vitro.scale, its higher-throughput platform. Customer testing of vitro.scale is expected to begin in 2027, ahead of its planned 2028 launch.